This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Fibrinogen with human thrombin 40mg + 250 units/ml 2ml, 4ml, 10ml sealant

Updated 2 Feb 2023 | Surgical sealants

Presentation

Surgical sealant containing fibrinogen and human thrombin.

Drugs List

  • fibrinogen 160mg/2ml + human thrombin 1000 i.u./2ml sealant
  • fibrinogen 400mg/5ml + human thrombin 2500 i.u./5ml sealant
  • fibrinogen 80mg/ml + human thrombin 500 i.u./ml sealant
  • VERASEAL 160mg/2ml + 1000 i.u./2ml sealant
  • VERASEAL 400mg/5ml +2500 i.u./5ml sealant
  • VERASEAL 80mg/ml + 500 i.u./ml sealant
  • Therapeutic Indications

    Uses

    Adjunctive haemostatic in surgery when other methods insufficient

    Supportive treatment in adults where standard surgical techniques are insufficient:
    for improvement of haemostasis,
    as suture support: in vascular surgery.

    Dosage

    Adults

    The volume of sealant to be applied and the frequency of application depends on the underlying clinical needs of the individual patient, the type of surgical intervention, the size of the area, the mode of application and the number of applications.

    In clinical trials the individual dosage ranged from 0.3ml to 12ml. Larger volumes may be required for some procedures.

    The initial volume to be applied should be sufficient to entirely cover the intended application area. The application may be repeated if required.

    Administration

    For epilesional administration.

    The surface of the wound should be as dry as possible before the sealant is applied.

    Application by dripping
    Keep the tip of the applicator as close to the tissue surface as possible (not touching the tissue) and apply individual drops to the area to be treated.

    Application by spraying
    Connect the applicator to the pressure regulator according to the manufacturers instructions.

    The solution should be sprayed at least 2cm away from the target tissue. Increase distance accordingly to achieve desired coverage of the target area.

    Contraindications

    Severe or brisk arterial haemorrhage

    Precautions and Warnings

    Children under 18 years
    Breastfeeding
    Pregnancy

    Derived from human proteins - transmission of infective agents possible
    Cover all the tissue adjacent to the site of sealing before application
    Record name and batch number of administered product
    Remove solutions containing alcohol/iodine/heavy metals before application
    Treatment to be administered under the supervision of a specialist
    For epilesional use only
    Management of cases of shock should follow current medical standards
    Discontinue if hypersensitivity reactions occur

    Unintentional intravascular application may lead to life threatening thromboembolic complications.

    The sealant should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy.

    Apply sealant as a thin layer. Excessive clot thickness may impair efficacy and the wound healing process.

    Fibrinogen with human thrombin sealant should not be used in tissue gluing, neurosurgery, gastrointestinal anastomoses or application through a flexible endoscope for treatment of bleeding.

    Pregnancy and Lactation

    Pregnancy

    Use fibrinogen with human thrombin sealant with caution during pregnancy.

    The manufacturer does not recommend using fibrinogen with human thrombin sealant during pregnancy unless it is clearly needed. At the time of writing there is limited published information regarding the use of fibrinogen with human thrombin sealant during pregnancy. Potential risks are unknown.

    Lactation

    Use fibrinogen with human thrombin sealant with caution during breastfeeding.

    The manufacturer does not recommend breastfeeding whilst using fibrinogen with human thrombin sealant unless it is clearly needed. The presence of fibrinogen with human thrombin in human breast milk and the effects on exposed infants are unknown.

    Side Effects

    Abnormal INR
    Abscess
    Alanine aminotransferase increased
    Anaemia
    Anaphylaxis
    Angioedema
    Antibody formation
    Anxiety
    Aspartate aminotransferase increased
    Atrial fibrillation
    Back pain
    Bladder spasm
    Bronchospasm
    Cellulitis
    Chest tightness
    Chills
    Conjunctival irritation
    Constipation
    Contusion
    Deep vein thrombosis (DVT)
    Dyspnoea
    Dysuria
    Ecchymosis
    Elevated blood glucose (transient)
    Emboli formation
    Erythema
    Flatulence
    Flushing
    Haematoma
    Haemoglobin decrease
    Haemorrhage
    Haemorrhagic anaemia
    Headache
    Hives
    Hyperglycaemia
    Hyperkalaemia
    Hypersensitivity reactions
    Hypertension
    Hyperthermia
    Hypocalcaemia
    Hypoglycaemia
    Hypokalaemia
    Hypomagnesaemia
    Hyponatraemia
    Hypoproteinaemia
    Hypotension
    Hypoxia
    Ileus
    Increase in serum transaminases
    Increased partial thromboplastin time
    Infections
    Insomnia
    Lethargy
    Leukocytosis
    Leukopenia
    Local burning
    Nausea
    Operative wound haemorrhage
    Painful extremities
    Parvovirus B19 infection
    Peripheral oedema
    Peritonitis
    Plasma cell myeloma
    Pleural effusion
    Pleurisy
    Post procedural haemorrhage
    Procedural hypotension
    Procedural pain
    Prothrombin time increased
    Pruritus
    Pulmonary embolism
    Pulmonary oedema
    Pyrexia
    Restlessness
    Retroperitoneal haematoma
    Rhonchi
    Serum bilirubin increased
    Somnolence
    Stinging
    Tachycardia
    Tingling sensation
    Urinary retention
    Urticaria
    Vascular graft complications
    Vascular graft occlusion
    Vascular graft thrombosis
    Ventricular tachycardia
    Vessel puncture site haematoma
    Vomiting
    Wheezing
    Wound secretion

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111.

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: November 2020

    Reference Sources

    Summary of Product Characteristics: VeraSeal solutions for sealant. Instituto Grifols, S.A. Revised November 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.